# EDGAR Filing Document

**Accession Number:** 0001962738
**File Stem:** 0001104659-23-014964
**Filing Date:** 2023-2
**Character Count:** 2406
**Document Hash:** f2a63922b5c821b17affe42a0c719e3c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-014964.hdr.sgml**: 20230314

**ACCESSION NUMBER**: 0001104659-23-014964

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230209

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CASI Pharmaceuticals Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001962738
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 1701-1702, CHINA CENTRAL OFFICE TOWER 1
- **STREET 2:** NO. 81 JIANGUO ROAD, CHAOYANG DISTRICT
- **CITY:** BEIJING
- **STATE:** F4
- **ZIP:** 100025
- **BUSINESS PHONE:** 86 10 6561 8789

**MAIL ADDRESS:**
- **STREET 1:** 1701-1702, CHINA CENTRAL OFFICE TOWER 1
- **STREET 2:** NO. 81 JIANGUO ROAD, CHAOYANG DISTRICT
- **CITY:** BEIJING
- **STATE:** F4
- **ZIP:** 100025

**CASI PHARMACEUTICALS HOLDINGS, INC.**

1701-1702, China Central Office Tower 1

No. 81 Jianguo Road Chaoyang District

Beijing, 100025

People's Republic of China

February 9, 2023

**VIA EDGAR**

Mr. Joshua Gorsky

Division of Corporation Finance

Office of Life Sciences

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **CASI Pharmaceuticals Holdings, Inc.** |

---

**Registration Statement on Form F-4, as amended**

**File No. 333-269479**

Dear Mr. Gorsky:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), CASI Pharmaceuticals Holdings, Inc. (the "Company") hereby requests that the effective date of the Company's Registration Statement on Form F-4 (File No. 333-269479) be accelerated by the Securities and Exchange Commission to 4:00 p.m., Washington D.C. time on Monday, February 13, 2023, or as soon thereafter as may be practicable.

In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Please contact Rui Zhang, at 617-945-6381 or ruiz@casipharmaceuticals.com if you have any questions. Thank you very much.

[*Signature page follows*]

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| CASI Pharmaceuticals Holdings, Inc. | CASI Pharmaceuticals Holdings, Inc. |
| By: | /s/ Kun Qian |
| Name: | Kun Qian |
| Title: | Principal Executive Officer |

---